- The FDA has reviewed NeuroOne Medical Technologies Corporation's NMTC appeal for 510(k) clearance for its Evo sEEG Electrode for less than 30-day use.
- In a letter to the company, the FDA stated that they upheld their decision that the device is not substantially equivalent for extended use based on their analysis of the methodology used for exhaustive extraction testing.
- The FDA also stated that NeuroOne Medical might submit a new 510(k) with new evidence related to the subacute toxicity endpoint to support a finding of substantial equivalence.
- The company is collecting the required data and intends to submit a Special 510(k), which according to FDA guidance, is processed within 30 days of receipt, rather than the 90 days for a traditional 510(k).
- The company expects to resubmit the application to the FDA in August 2022.
- "In addition, the company will immediately explore the opportunity to market the device through Zimmer Biomet Holdings Inc ZBH for intraoperative use to gain product clinical experience while we progress with the re-submission to the FDA," said Dave Rosa, CEO.
- In September 2021, the company received FDA clearance to market the Evo sEEG Electrode for temporary (less than 24 hours) use with equipment for the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain.
- Price Action: NMTC shares are down 3.81% at $0.56 during the market session on the last check Tuesday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.
All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.
Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.
Rate collection and criteria: Click here for more information on rate collection and criteria.